EUCTR2005-005975-13-EE进行中（未招募）不适用
Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with all the following criteria were eligible for enrolment:
- •- 18 to 65 year-old male or female ambulatory patient,- suffering from a seasonal allergic rhinitis to grass pollen grain defined by :- a recorded medical history of seasonal rhinitis (May to July) with symptoms (sneezing and/or palate itching and/or aqueous rhinorrhea and/or nasal blockade) for at least two years, - a positive prick test to grass pollen grains, and/or class 3 or more specific IgE duly documented in the medical file within the past 6 months, - with a nasal symptomatology score equal or superior to 6 at inclusion (maximal score: 12)- willing and able to understand and sign an approved Informed Consent Form,- able to understand the protocol and to attend the control visits,- registered with a social security or health insurance system.
- •For women of child bearing potential:- use of an contraceptive method (oral contraceptive, intra-uterine device, tubal surgery, double barrier method: spermicide gel + condom).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Non inclusion criteria:Patients with one of the following criteria were not eligible for enrolment:* Criteria related to pathologies- Any cardio-vascular, renal, hepatic, gastro-intestinal, endocrine, haematological, neuro-psychiatric severe diseases that was not compatible with the participation to the study in the opinion of the investigator, - Any acute or chronic disease that did not allow with the participation to the study in the opinion of the investigator,- Chronic alcoholism,- Glaucoma or prostate adenoma,- History of agranulocytosis,- Congenital galactosemia, malabsorption syndrom to glucose or galactose, or galactase deficiency,- Seizure,- Asthma treated with corticosteroids,- Symptomatic allergic rhinitis out of the grass pollen season,- Iatrogenic rhinitis,- Nasal polyposis or severe deviation of the nasal septum, - Upper respiratory tract infection within the last 3 weeks.* Criteria related to treatments- Medical history of hypersensitivity to mequitazine or drug excipients,- Specific desensitization to grass pollens within the last 5 years,- Corticosteroid treatment within the last 6 months (delayed steroids) or within the last 4 weeks (local, inhaled or systemic routes), - Treatment by cromone or ketotifen within the last 2 weeks,- Treatment by antihistamine within the last 2 weeks,- Treatment by NSAIDs (other than oxicams) within the last three days,- Treatment by oxicams within the last 8 days,- Treatment by nasal or systemic decongestive drug (wash-out 24 hours), tricyclic antidepressants (wash-out 1 month), MAO inhibitors (wash-out 1 month), atropine-like drugs (wash-out 1 month), any other treatment that could induce induction or inhibition of hepatic microsomial metabolism (wash-out period of 1 month).* Criteria related to the population- participation to another clinical trial in the previous month or during the study,- patient who, in the judgement of the investigator is not likely to be compliant during the study,- patient who has forfeited his/her freedom by administrative or legal award, or who is under guardianship,- subject who cannot be contacted in case of emergency.For women:- pregnancy or breast feeding.
研究者
相似试验
进行中（未招募）
1 期
Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.Seasonnal Allergic rhinitis Prospective, multicentric, international, randomised, double-blind trial in six parallel groups: 4 doses of the test product, active control and placebo. This study is intended to evaluate the efficacy and a dose response of V0114 (l-MEQUITAZINE) in a clinical situation with patients having a hay fever.EUCTR2005-005975-13-FRPIERRE FABRE MEDICAMENT600
进行中（未招募）
1 期
Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.Prospective, multicentric, international, randomised, double-blind trial in six parallel groups: 4 doses of the test product, active control and placebo. This study is intended to evaluate the efficacy and a dose response of V0114 (l-MEQUITAZINE) in a clinical situation with patients having a hay fever.EUCTR2005-005975-13-CZPIERRE FABRE MEDICAMENT600
进行中（未招募）
1 期
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal doseidiopathic or diabetic gastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: LLTClassification code 10021227Term: Idiopathic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002254-86-PLDr. Falk Pharma GmbH320
招募中
2 期
Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at least moderate idiopathic or diabetic gastroparesisNL-OMON53662Dr. Falk Pharma GmbH28
招募中
1 期
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal doseEUCTR2021-002254-86-NLDr. Falk Pharma GmbH320